ValuEngine upgraded shares of Voyager Therapeutics (NASDAQ:VYGR) from a sell rating to a hold rating in a research note issued to investors on Monday morning.
Other equities analysts have also issued reports about the company. BidaskClub lowered Voyager Therapeutics from a strong-buy rating to a buy rating in a research report on Friday, February 2nd. BTIG Research initiated coverage on Voyager Therapeutics in a research report on Tuesday, December 19th. They set a buy rating and a $32.00 price target on the stock. Canaccord Genuity reissued a buy rating and set a $26.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, January 23rd. Piper Jaffray reissued a buy rating and set a $40.00 price target on shares of Voyager Therapeutics in a research report on Monday, March 12th. Finally, Zacks Investment Research raised Voyager Therapeutics from a hold rating to a buy rating and set a $26.00 price target on the stock in a research report on Friday, March 16th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company’s stock. Voyager Therapeutics currently has a consensus rating of Buy and a consensus price target of $29.73.
Voyager Therapeutics stock opened at $18.13 on Monday. Voyager Therapeutics has a one year low of $8.10 and a one year high of $31.91.
In other news, insider Bernard Ravina sold 2,451 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $18.24, for a total value of $44,706.24. Following the completion of the sale, the insider now directly owns 4,902 shares in the company, valued at approximately $89,412.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Jane Henderson sold 17,316 shares of the business’s stock in a transaction that occurred on Monday, March 19th. The shares were sold at an average price of $22.11, for a total value of $382,856.76. Following the completion of the sale, the chief financial officer now owns 15,416 shares of the company’s stock, valued at $340,847.76. The disclosure for this sale can be found here. Insiders sold a total of 68,087 shares of company stock valued at $1,588,741 over the last quarter. Company insiders own 8.00% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. MetLife Investment Advisors LLC bought a new stake in shares of Voyager Therapeutics in the 4th quarter valued at approximately $128,000. Iguana Healthcare Management LLC increased its holdings in shares of Voyager Therapeutics by 100.0% in the 4th quarter. Iguana Healthcare Management LLC now owns 50,000 shares of the company’s stock valued at $830,000 after acquiring an additional 25,000 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Voyager Therapeutics in the 4th quarter valued at approximately $4,579,000. Teachers Advisors LLC grew its stake in Voyager Therapeutics by 42.0% during the 4th quarter. Teachers Advisors LLC now owns 32,814 shares of the company’s stock worth $545,000 after buying an additional 9,699 shares during the last quarter. Finally, Ardsley Advisory Partners bought a new position in Voyager Therapeutics during the 4th quarter worth $415,000. Institutional investors and hedge funds own 78.22% of the company’s stock.
WARNING: This piece was first published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3335002/valuengine-upgrades-voyager-therapeutics-vygr-to-hold.html.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.